前列腺特异性膜抗原PET/CT检测前列腺癌甲状腺及环状软骨转移
该研究回顾了2022年4月至2023年10月期间221例接受18F-PSMA或68Ga-PSMA PET/CT的高危前列腺癌初诊分期或生化复发再分期患者,其中4例检出喉软骨(甲状腺及环状软骨)转移。PSMA PET/CT较高的敏感性和特异性有助于发现以往隐匿的转移灶。
要点
- 221例接受PSMA PET/CT的前列腺癌患者中,4例检出甲状腺及环状软骨转移。
- PSMA PET/CT可检测到以往认为极罕见、文献仅少数报道的喉软骨转移。
- PSMA PET/CT敏感性和特异性提高,有助于发现既往隐匿的转移性疾病。
核心结论
- PSMA PET/CT可检出前列腺癌向甲状腺及环状软骨的转移,这类转移以往被认为极罕见。
研究设计与样本
- 2022年4月至2023年10月,221例高危前列腺癌初诊分期或生化复发再分期患者接受18F-PSMA(Pylarify)或68Ga-PSMA(Illuccix)PET/CT检查。
主要发现
- 221例接受PSMA PET/CT检查的患者中,4例检出前列腺癌喉软骨(甲状腺及环状软骨)转移。
- PSMA PET/CT敏感性和特异性提高,可检测以往隐匿的转移性疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) PET/CT has revolutionized the imaging of prostate cancer. Historically, prostate cancer metastasis to thyroid and cricoid cartilages was thought to be exceedingly rare, with only a few reported cases in the literature. Prostate cancer metastasis to the laryngeal cartilages was detected in 4 of 221 patients who underwent imaging with 18 F-PSMA (Pylarify) or 68 Ga-PSMA (Illuccix) PET/CT for initial staging of high-risk prostate cancer or restaging evaluation in the setting of biochemical recurrence from April 2022 through October 2023. The increased sensitivity and specificity of PSMA PET/CT allow for the detection of previously occult metastatic disease.
引用
- Eichhorn J, Nelson N, Raichandani S, et al. Prostate-Specific Membrane Antigen PET/CT Detection of Prostate Cancer Metastasis to Thyroid and Cricoid Cartilages. Clin Nucl Med. 2024. PMID: 38389203. doi:10.1097/RLU.0000000000005111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。